Kornimate/medical-research-clean huggingface dataset:
cognitive enhancement through computerized training

Conditions: Alcohol Use Disorder

Summary: alcohol use disorder is characterized by widespread neurocognitive impairments, however despite substantial advances in the intervention and treatment of alcohol use disorders, exceptionally few studies have been directed to improving these deficits. this project leverages computerized cognitive training, applied as an adjunct to inpatient treatment, to enhance neurocognitive recovery. this project informs public health and future intervention efforts by interrogating factors critical to intervention efficacy and clarifying relationships between neurocognitive recovery and treatment outcomes, including post-discharge alcohol consumption.

programmatic investigation of neurocognitive functioning in alcohol use disorder (aud) has revealed widespread and sustained impairments. despite conceptual relevance to treatment efficacy, few aud interventions have been directed to the remediation of these impairments. this project is responsive to this gap. it will answer critical questions regarding the potential of cognitive training (ct), applied as an adjunct to inpatient treatment, to improve cognitive recovery and post-discharge functional outcomes in aud. the current project will investigate the efficacy of two experimental cognitive training interventions in a sample of inpatients in treatment for aud. while the effectiveness of ct to enhance function is supported by diverse literatures, it remains largely unexamined in aud. the current project will interrogate the degree to which cognitive training interventions can "transfer" cognitive gains to untrained tasks/domains, and improve overall executive functioning. it will apply conceptual models from the ct and alcohol literatures to identify factors associated with ct efficacy. the impact of cognitive training on functional outcomes, including post-discharge drinking, will be investigated. finally, relationships between cognitive recovery during treatment and post-discharge adaptation will be examined. thus, the current work will be of substantial import to public health, alcohol science, and will inform future intervention efforts.

Eligibility criteria:
inclusion criteria: * minimum of 10 years of education * meet dsm-5 criteria for alcohol use disorder exclusion criteria: * medical histories confounding interpretation regarding change in neuropsychological functioning (e.g., stroke) * meet dsm-5 criteria for current/unremitted psychotic, panic, or bipolar disorders

Keywords: cognitive training alcohol use disorder
treatment of chronic active antibody mediated rejection with tocilizumab

Conditions: Kidney Transplant Rejection

Summary: chronic active antibody mediated rejection (camr) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (amr). annually, 5000 kidney transplants are lost in the united states due to camr. the two-year graft survival rate in camr is approximately 20%, highlighting the need for a more efficient therapy for camr and directly targeting donor specific antibody (dsa) producing cells and reducing camrthere is no established treatment for this problem. while many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, ivig, and rituximab, although effective in treating amr, have not been successful in reducing dsa or improving kidney graft survival in camr patients. despite these treatments, two-year graft survival can increase up to 55%. the use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.

the trial is an open-labeled randomized clinical trial that evaluates the safety and efficacy of tocilizumab as an add-on therapy to standard of care treatment of plasmapheresis, ivig, and rituximab in treatment of camr in kidney transplant recipients.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent 2. egfr\> 25 cc/min 3. chronicity index \<8 4. ifta\<40% 5. ebv igg positive exclusion criteria: 1. active or recurrent infections 2. history of malignancy, unless in remission for more than 2 years with no relapse 3. abnormal liver function tests 4. platelet \< 100,000
effects of vibrations on the biceps brachii muscle and grip strength

Conditions: Muscle Strength

Summary: it has been suggested that applying acute vibration exercises enhances muscle force, like several weeks of resistance training. the present study investigated the effects of local vibration with two different frequencies on biceps brachii isometric muscle strength and grip strength in healthy young men. isometric strength of the biceps brachii muscle and grip strength were assessed at baseline and after vibration training (immediate, 10 minutes, and 20 minutes post vibration training).


Eligibility criteria:
inclusion criteria: * healthy adult males exclusion criteria: * history of recent upper extremity injury * sensory deficits in the upper extremity * history of recent upper extremity surgery * participation in any resistance training

Keywords: vibration training biceps brachii muscle strength handgrip
a study of avelumab in patients with locally advanced or metastatic urothelial cancer (javelin bladder 100)

Conditions: Urothelial Cancer

Summary: the main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (bsc) with bsc alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium * stage iv disease at the start of first-line chemotherapy * measurable disease (per recist v1.1) prior to the start of first-line chemotherapy * prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine + cisplatin and/or gemcitabine + carboplatin * no evidence of progressive disease following completion of first-line chemotherapy (i.e., ongoing cr, pr, or sd per recist v1.1 guidelines ) exclusion criteria: * prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization * prior immunotherapy with il-2, ifn-α, or an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or ctla 4 antibody (including ipilimumab), or any other antibody or drug specifically targeting t-cell co-stimulation or immune checkpoint pathways * persisting toxicity related to prior therapy (grade \>1 nci ctcae v4.0); however, alopecia, sensory neuropathy (grade 2 or less), or other (grade 2 or less) adverse events not constituting a safety risk based on the investigator's judgement are acceptable. * patients with known symptomatic central nervous system (cns) metastases requiring steroids * diagnosis of any other malignancy within 5 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.

Keywords: bladder cancer urologic neoplasms urothelial carcinoma pd-l1 programmed cell death protein maintenance treatment
mobile health to enhance exercise in type 2 diabetes

Conditions: Diabetes Mellitus, Type 2; Telemedicine; Mobile Applications; Exercise Therapy

Summary: being physically active and exercising is important for the treatment of type 2 diabetes as it helps control blood sugar and improve physical function. lots of people find it hard to be physically active and sticking with exercise is difficult for most people. in this project we will investigate two strategies to support people with type 2 diabetes to increase and then maintain a physically active lifestyle, which includes exercising regularly. participants in one group (exercise counselling) will complete a 6-month structured exercise and physical activity programme supported by regular (virtual) contact with an exercise specialist. participants in the second group (mobile health technology (mhealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (app). the fitness watch and mobile app will allow the exercise specialist to provide greater support and feedback throughout the programme.


Eligibility criteria:
inclusion criteria: * diagnosed with t2d within the previous 5-24 months * male or female * aged 40-75 * treat diabetes with only metformin or lifestyle modifications (diet and exercise) * for those prescribed metformin: have used a stable dose for 3-months or more exclusion criteria: * aged under 40 or over 75 * glycated hemoglobin level (hba1c) more than 10% (\>86mmol/mol) * blood pressure higher than 160/110 mmhg * treat diabetes with an antidiabetic drug other than metformin (sulfonylureas, thiazolidinedione, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonist, acarbose, meglitinides) * prescription of insulin * unstable angina (frequent chest pain) * myocardial infarction (heart attack) within the previous 3 months * transient ischemic attack (tia) within the previous 6 months * heart failure ≥class 2 * arrhythmia * inability to increase activity * pregnancy or planning to become pregnant * less than 6 months post childbirth or stopped breastfeeding less than 1 month ago * not owning a smartphone/ or having no data plan or access to wifi * currently meeting the recommended exercise guidelines (150 min of moderate intensity exercise per week).

Keywords: humans blood glucose exercise life style counseling biomedical technology
using light therapy to treat toe nail fungus

Conditions: Onychomycosis

Summary: to see if four sessions of light therapy successfully treats nail fungus.

this study is a one year study which includes four treatment sessions of light therapy looking for clinical and mycological improvement.

Eligibility criteria:
inclusion criteria: * toe nail fungus, not infolving lunula * between ages 18-70 years old exclusion criteria: * not on systemic anti-fungal medications

Keywords: toe nail fungus
efficacy and safety of rituximab given at fixed dose (1000 mg on days 1 and 15) compared to the standard regimen in adult's immune thrombocytopenia

Conditions: Primary Immune Thrombocytopenia

Summary: the aim of this large french multicentric retrospective study was to compare the efficacy and safety of two (the standard and the rheumatoid arthritis) rituximab regimens in adult's immune thrombocytopenia .

every adult (age ≥ 18 years) seen in one of the 3 participating centre (dijon, marseille, mondor) over a 7-year period (2005-2012) with a definite diagnosis of primary itp according to the american society hematology guidelines who received rtx regardless the regimen could be included.

Eligibility criteria:
inclusion criteria: * primary itp * age \> 18 years exclusion criteria: * secondary itp * age \< 18 years

Keywords: itp rituximab efficacy anti-cd20 regimen
anticariogenic properties of zamzam water

Conditions: Caries,Dental; Caries Active

Summary: the present study aims to evaluate and compare the effect of zamzam water as mouthwashes in high caries-risk patients regarding: i. streptococcus mutans (s. mutans) count. ii. oral ph. after 3 and 6 months interval.

the present study aims to evaluate and compare the effect of zamzam water mouthwashes in high caries-risk patients regarding: i. streptococcus mutans (s. mutans) count. ii. oral ph. all patients will be into two groups; the first group will use zamzam water mouthwash for a six months with other preventive protocols including fissure sealants and preventive restorations wherever needed, while the second group will undergo preventive protocols only. during these six months, patients will be reassessed at three and six-month intervals regarding s. mutans count, oral ph, and caries risk level.

Eligibility criteria:
inclusion criteria: * male or female participants aged between 18-35 years. * systemically- free individuals. * high caries-risk patients according to ada (american dental association). * not on a medication interfering with salivary secretion. * co-operative patients approved to participate in the study. exclusion criteria: * patients who are already on any mouthwash regime. * patients who are on any medication that would alter the salivary secretion. * allergy to any of the ingredients of the study products.
cgm use in adults with type 2 diabetes on basal insulin

Conditions: Diabetes Mellitus, Type 2

Summary: a prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period. the purpose of this study is to determine whether continuous glucose monitoring using freestyle libre 3 will improve hba1c compared to smbg over 16 weeks in adults with sub-optimally controlled (hba1c 7.5-11%) type 2 diabetes on basal therapy.

the study will assess change in hba1c as the primary endpoint. other endpoints related to glycaemic control are included in the analyses. the study is split into two phases each of four months duration: participant-driven (phase 1) and hcp/therapy-driven (phase 2). participants will be randomised to either freestyle libre 3 or to continuation with their current smbg device.

Eligibility criteria:
inclusion criteria: * aged 18 years or over. * type 2 diabetes diagnosis for ≥1 year prior to enrolment. * type 2 diabetes treated with a basal insulin injection regimen and sglt2 inhibitor and/or glp-1. * screening hba1c ≥59 mmol/mol to ≤97 mmol/mol (≥7.5% and ≤11.0%, inclusive). exclusion criteria: * participant is currently prescribed prandial or pre-mixed (biphasic) insulin at enrolment. * currently participating in another study that could affect glucose measurements or glucose management. * a female participant who is pregnant. * a breastfeeding female participant. * bariatric surgical procedure within the past 12 months or is planning/scheduled for bariatric surgery within the study duration.
the effect of licorice root extract and pomegranate juice on atherosclerotic parameters in diabetic patients

Conditions: Diabetes Mellitus; Atherosclerosis

Summary: the study will check whether taking 100 mg of licorice root extract or 250 cc of pomegranate juice daily by men with diabetes mellitus who are non-smokers and already treated with statins decreases the risk of developing atherosclerosis. the hypothesis of the study is that natural anti-oxidants (such as licorice root extract and pomegranate juice), by scavenging free radicals, retard and may even reverse atherosclerosis.


Eligibility criteria:
inclusion criteria: * male * diabetes mellitus exclusion criteria: * younger than 18 * smoker * receiving fibrates
a study of eligard® in hormone-dependent prostate cancer patients

Conditions: Prostate Cancer

Summary: the objective of this study was to evaluate the safety profile of eligard® in ethnic asian prostate cancer patients.


Eligibility criteria:
inclusion criteria: * a patient for whom the physician has decided to initiate treatment with a luteinizing hormone releasing hormone (lhrh) agonist in standard clinical practice * biopsy-proven prostate adenocarcinoma * locally advanced prostate cancer with biochemical relapse radical prostatectomy and/or radiotherapy, or hormonal treatment-naive advanced or metastatic prostate cancer patient who has not received chemotherapy and has no plans to undergo treatment with chemotherapy at study entry. * patient who indicates that once the study is completed, he expects having access to androgen deprivation therapy (adt), either medical or surgical, within the local healthcare system (either through public/ private health insurance or out of pocket payment). exclusion criteria: * patient with castrate resistant prostate cancer * patient who previously underwent bilateral orchiectomy * patient who has received prior treatment with lhrh analogues * prior or concomitant treatment with systemic chemotherapy. a patient where there is a likelihood to receive systemic chemotherapy should not be enrolled * life expectancy of \< 1 year due to comorbidities * participation in another interventional clinical trial within one month prior to study entry or during the duration of the study * patient who plans to receive intermittent adt at the time of study entry * patient receiving non-palliative radiotherapy within 3 months prior to study entry * patient receiving adjuvant adt in combination with definitive radiotherapy * patient with metastatic hormonal treatment-naive prostate cancer, for whom chemo-hormonal treatment (combination of docetaxel and adt) is indicated. * patient with hypersensitivity to gonadotropin releasing hormone (gnrh), gnrh agonist analogs or any of the components of eligard® * patient with any contraindication for eligard® use based on local prescribing information

Keywords: leuprolide acetate prostate cancer
clinical effectiveness and impact on health-related quality of life in peruvian patients with psoriasis after 16 weeks of adalimumab therapy

Conditions: Moderate to Severe Psoriasis

Summary: adalimumab has recently been authorized for active psoriasis in peru and local experience is very low. the aim of this study is to obtain peruvian data of clinical effectiveness and impact on health-related quality of life with the use of adalimumab in participants with chronic plaque psoriasis complying with the dosing and monitoring recommendations of the local approved label.


Eligibility criteria:
inclusion criteria: * participants with moderate to severe chronic plaque psoriasis defined as psoriasis area and severity index (pasi) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate * participant is capable of and willing to give written informed consent and to comply with the requirements of the study protocol exclusion criteria: * participants should not be enrolled if they cannot be treated in accordance with the local product label * participants enrolled into another study or clinical trial * history of hepatitis b infection * history of neurologic symptoms suggestive of central nervous system demyelinating disease * history of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix) * active tuberculosis infection before initiating adalimumab treatment or latent tuberculosis infection not able to take complete prophylactic treatment * pregnant or lactating female, demonstrated by a pregnancy test before entering the study and willing to use a contraceptive method * use of another anti-tumoral necrosis factor previously * history of congestive heart failure * any other condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or subjects participants to an unacceptable risk * participants with active infection including chronic or localized infections until infections are controlled * history of sensitivity to latex * participants who will receive concomitant phototherapy and systemic therapy during adalimumab therapy

Keywords: adalimumab therapy psoriasis observational study
evaluation and treatment of adhesive capsulitis using non-invasive neurostimulation devices

Conditions: Adhesive Capsulitis of the Shoulder; Frozen Shoulder

Summary: the goal of this randomized controlled trial is to compare the integrity of somatosensory processing with transcranial magnetique stimulation (tms) and corticospinal excitability of the affected shoulder in individuals with adhesive capsulitis versus healthy controls. the secondary objective is to compare the clinical and neurophysiological effects of an intervention using tendon vibration (vib) to induced kinesthetic illusions. this will involve comparing two groups: one receiving a real intervention versus a placebo intervention protocol, both coupled with standardized exercises in individuals with capsulitis. the hypotheses are that the proprioceptive processing and corticospinal excitability are impaired in the presence of capsulitis, and that the vib + exercises intervention will result in greater improvements than the placebo vib + exercises. to goal is to establish the first empirical foundations for understanding adhesive capsulitis, using cutting-edge neurophysiological investigation technologies. tms will be used to explore the presence of maladaptive plasticity in motor networks by assessing the excitability and integrity of the primary motor cortex (m1) and the corticospinal tract. recruitement: 30 healthy participants and 30 participants with a diagnosis of adhesive capsulitis will undergo 2 baselines assesments, 6 interventions with tendon vibration and 2 follow-up evaluation. participants will be age- and sex-matched. baseline and follw-up include: * questionnaires : spadi, quickdash, french version of the mcgill pain questionnaire; * active and passive range of motion; * ultrasound for diagnosing capsulitis. comparison parameters: * active motor threshold (amt) * motor evoked potential (mep) latency and amplitude * standardized kinesthetic illusion procedure (skip) : direction of illusion, clearness, amplitude/speed. interventions : * 2 baselines including all questionnaires, ultrasound, active and passive range of motion, tms procedure and skip; * 2 vib interventions per week, for 3 weeks * real vib : 80hz of vibration to induce kinesthetic illusions, * placebo vib : 40hz of vibration that does not induce kinesthetic illusions * 2 follow-up including all questionnaires, ultrasound, active and passive range of motion, tms procedure and skip.


Eligibility criteria:
inclusion criteria: * 18 years old and over * good general health * adhesive capsulitis (experimental group) or * no shoulder pain (placebo group) exclusion criteria: * cognitive disorders; * any neurological disease/injury affecting the upper limbs; * history or diagnosis of muscle, tendon, or capsular tear; * shoulder surgery/prosthesis; * pregnant woman; * presence of metal in the skull or jaw; * history of epilepsy.

Keywords: adhesive capsulitis frozen shoulder tendon vibration transcranial magnetique stimulation proprioception kinesthetic illusions
study evaluating gap-486 on heart rhythm in patients with coronary artery disease

Conditions: Arrhythmia

Summary: the purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe.


Eligibility criteria:
inclusion criteria: * patients with or without icds (implantable cardioverter defibrillators) * patients undergoing an electrophysiology study for evaluation of ventricular rhythm * patients with a history of heart disease exclusion criteria: * patients with uncontrolled blood pressure * patients with certain cardiac risk factors * patients with significant kidney or liver problems

Keywords: arrhythmia antiarrhythmic programmed electrical stimulation